
Photo taken from mdanderson.org
Aug 9, 2024, 02:31
E2-RADIatE Oligo Care cohort, largest prospective registry cohort on oligometastatic disease – EORTC
EORTC shared a post on LinkedIn:
“We are excited to share a new publication about the E2-RADIatE Oligo Care cohort, the largest prospective registry cohort on oligometastatic disease.
This interim analysis of approximately 1600 oligometastatic patients aimed to evaluate acute toxicity within 6 months following stereotactic body radiotherapy (SBRT).
Toxicity within 6 months was low, confirming that SBRT is safe to use in the oligometastatic setting.”
Source: EORTC/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 16:16
Feb 22, 2025, 16:04
Feb 22, 2025, 16:00
Feb 22, 2025, 15:54
Feb 22, 2025, 15:48
Feb 22, 2025, 15:33
Feb 22, 2025, 15:14
Feb 22, 2025, 15:04
Feb 22, 2025, 14:43
Feb 22, 2025, 14:10
Feb 22, 2025, 13:28
Feb 22, 2025, 13:10